177 related articles for article (PubMed ID: 27401245)
1. c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.
Liu H; Ai J; Shen A; Chen Y; Wang X; Peng X; Chen H; Shen Y; Huang M; Ding J; Geng M
Clin Cancer Res; 2017 Feb; 23(4):974-984. PubMed ID: 27401245
[No Abstract] [Full Text] [Related]
2. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Shen A; Wang L; Huang M; Sun J; Chen Y; Shen YY; Yang X; Wang X; Ding J; Geng M
Cancer Res; 2015 Nov; 75(21):4548-59. PubMed ID: 26483207
[TBL] [Abstract][Full Text] [Related]
3. RAS-MAPK Reactivation Facilitates Acquired Resistance in
Bockorny B; Rusan M; Chen W; Liao RG; Li Y; Piccioni F; Wang J; Tan L; Thorner AR; Li T; Zhang Y; Miao C; Ovesen T; Shapiro GI; Kwiatkowski DJ; Gray NS; Meyerson M; Hammerman PS; Bass AJ
Mol Cancer Ther; 2018 Jul; 17(7):1526-1539. PubMed ID: 29654068
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
6. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
8. Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.
Ciccarelli C; Di Rocco A; Gravina GL; Mauro A; Festuccia C; Del Fattore A; Berardinelli P; De Felice F; Musio D; Bouché M; Tombolini V; Zani BM; Marampon F
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1685-1699. PubMed ID: 29959569
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Weeden CE; Holik AZ; Young RJ; Ma SB; Garnier JM; Fox SB; Antippa P; Irving LB; Steinfort DP; Wright GM; Russell PA; Ritchie ME; Burns CJ; Solomon B; Asselin-Labat ML
Mol Cancer Ther; 2017 Aug; 16(8):1610-1622. PubMed ID: 28611104
[TBL] [Abstract][Full Text] [Related]
10. Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Tateishi K; Iafrate AJ; Ho Q; Curry WT; Batchelor TT; Flaherty KT; Onozato ML; Lelic N; Sundaram S; Cahill DP; Chi AS; Wakimoto H
Clin Cancer Res; 2016 Sep; 22(17):4452-65. PubMed ID: 27076630
[TBL] [Abstract][Full Text] [Related]
11. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
13. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
[No Abstract] [Full Text] [Related]
14. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
15. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
16. ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Nakanishi Y; Mizuno H; Sase H; Fujii T; Sakata K; Akiyama N; Aoki Y; Aoki M; Ishii N
Mol Cancer Ther; 2015 Dec; 14(12):2831-9. PubMed ID: 26438159
[TBL] [Abstract][Full Text] [Related]
17. A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth.
Park J; Kim SY; Kim HJ; Kim KM; Choi EY; Kang MS
Oncotarget; 2016 May; 7(19):28670-83. PubMed ID: 27107424
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.
Sun H; Lin DC; Cao Q; Pang B; Gae DD; Lee VKM; Lim HJ; Doan N; Said JW; Gery S; Chow M; Mayakonda A; Forscher C; Tyner JW; Koeffler HP
Clin Cancer Res; 2017 Aug; 23(15):4376-4387. PubMed ID: 28336564
[No Abstract] [Full Text] [Related]
20. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway.
Zhang Y; Chen HX; Zhou SY; Wang SX; Zheng K; Xu DD; Liu YT; Wang XY; Wang X; Yan HZ; Zhang L; Liu QY; Chen WQ; Wang YF
Mol Cancer; 2015 Mar; 14():56. PubMed ID: 25890196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
